Immunome (IMNM) completes first cohort in Phase 1b COVID-19 antibody study; seeks partner

Immunome Inc.

First cohort of Phase 1b study of IMM-BCP-01 (COVID-19 antibody cocktail) dosed with no significant treatment-related adverse events.
Company plans to seek a partner to continue the trial and further development of IMM-BCP-01.
Entered into a Letter Agreement with Whitehead Institute modifying payment obligations under a 2009 license agreement with a collaborator.
Corporate presentation dated January 2023 posted on company website for investor and partner meetings.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Immunome Inc. amended Letter Agreement with Whitehead Institute for Biomedical Research (effective 2023-01-04).

Action: amendment
Agreement: license
Counterparty: Whitehead Institute for Biomedical Research
Effective: 2023-01-04

Exact text from the filing

On November 17, 2022, Immunome, Inc. (the “Company”) entered into a Letter Agreement (“Letter Agreement”) with the Whitehead Institute for Biomedical Research (“Whitehead”), which became effective on January 4, 2023 upon the satisfaction of the conditions described therein. The Letter Agreement supplements the Exclusive Patent License Agreement entered into between the Company and Whitehead on June 25, 2009 (as amended on December 17, 2009, March 21, 2013, August 21, 2017 and July 21, 2020, the “License Agreement”).

View on SEC.gov

Browse all material agreements →

Immunome Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-001704

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.